Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-009572
Filing Date
2017-02-10
Accepted
2017-02-10 16:42:37
Documents
1
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 5 SUBMISSION doc5.html 5  
1 FORM 5 SUBMISSION doc5.xml 5 8881
  Complete submission text file 0001209191-17-009572.txt   10438
Mailing Address 3172 PORTER DRIVE PALO ALTO CA 94034
Business Address
SPIEGELMAN DANIEL K (Reporting) CIK: 0001238403 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-33882 | Film No.: 17594103

Mailing Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121
Business Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121 (206) 801-2100
Cascadian Therapeutics, Inc. (Issuer) CIK: 0001412067 (see all company filings)

EIN.: 260868560 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research